Venus Concept Inc. (VERO)
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally.
Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.
The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system.
In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles.
The company is headquartered in Toronto, Canada.
235 Yorkland Blvd Suite 900
Toronto, Ontario M2J 4Y8
|Phone||877 848 8430|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Domenic Serafino||Chief Executive Officer and Director|
|Domenic Della Penna||Chief Financial Officer|
|Soren Maor Sinay||Chief Operating Officer|
|Michael Mandarello||General Counsel and Corporate Secretary|
|Ross J. Portaro||President of Global Sales|
|Anat Kotler||Vice President of Global Marketing and Product Management|
|Anna Georgiadis||Vice President of Global Human Resources|
|Kenji Shimizu||Interim Chief Innovation Officer|
Latest SEC Filings
|May 17, 2022||4||Statement of changes in beneficial ownership of securities|
|May 12, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 12, 2022||8-K||Current report|
|Apr 29, 2022||SC 13G/A||Statement of acquisition of beneficial ownership by individuals|
|Apr 26, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 26, 2022||DEF 14A||Other definitive proxy statements|
|Apr 25, 2022||8-K||Current report|
|Apr 8, 2022||S-8||Securities to be offered to employees in employee benefit plans|
|Mar 31, 2022||8-K||Current report|
|Mar 28, 2022||4||Statement of changes in beneficial ownership of securities|
|View All SEC Filings|